Clinical implications of CNS penetration of antiretroviral drugs (Q34769915)

4 August 2017

1 reference

title

Clinical implications of CNS penetration of antiretroviral drugs (English)

1 reference

4 August 2017

anti-retroviral agent

0 references

author name string

Heather E Wynn

series ordinal

1

1 reference

4 August 2017

Richard C Brundage

series ordinal

2

1 reference

4 August 2017

Courtney V Fletcher

series ordinal

3

1 reference

4 August 2017

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

16

1 reference

4 August 2017

9

1 reference

4 August 2017

595-609

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200216090-00002

4 August 2017

0 references

cites work

Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and nelfinavir

1 reference

12 December 2020

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

1 reference

12 December 2020

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

1 reference

12 December 2020

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy

1 reference

12 December 2020

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients

1 reference

12 December 2020

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

1 reference

12 December 2020

Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir

1 reference

12 December 2020

Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication

1 reference

12 December 2020

Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy.

1 reference

12 December 2020

Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.

1 reference

12 December 2020

Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus

1 reference

12 December 2020

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

1 reference

12 December 2020

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

1 reference

12 December 2020

HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy

1 reference

12 December 2020

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1 reference

12 December 2020

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir

1 reference

12 December 2020

Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples

1 reference

12 December 2020

Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

1 reference

12 December 2020

Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group

1 reference

12 December 2020

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

1 reference

12 December 2020

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

1 reference

12 December 2020

Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

The mammalian choroid plexus

1 reference

12 December 2020

Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain

1 reference

12 December 2020

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma

1 reference

12 December 2020

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

1 reference

12 December 2020

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

1 reference

12 December 2020

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy

1 reference

12 December 2020

Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients.

1 reference

12 December 2020

Indinavir in cerebrospinal fluid of HIV-1-infected patients

1 reference

12 December 2020

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

1 reference

12 December 2020

Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children

1 reference

12 December 2020

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.

1 reference

12 December 2020

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

1 reference

12 December 2020

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

1 reference

12 December 2020

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

1 reference

12 December 2020

Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats

1 reference

12 December 2020

Indinavir plasma protein binding in HIV-1-infected adults

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Diurnal variation of alpha 1-acid glycoprotein concentration in normal volunteers.

1 reference

12 December 2020

Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis.

1 reference

12 December 2020

Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage

1 reference

12 December 2020

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

1 reference

12 December 2020

The pharmacokinetics of zidovudine administered by continuous infusion in children

1 reference

12 December 2020

Sanctuary sites in HIV-1 infection

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system.

1 reference

12 December 2020

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial

1 reference

12 December 2020

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study

1 reference

12 December 2020

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine

1 reference

12 December 2020

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine

1 reference

12 December 2020

The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine

1 reference

12 December 2020

Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors

1 reference

12 December 2020

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex

1 reference

12 December 2020

Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir

1 reference

12 December 2020

In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor

1 reference

12 December 2020

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

12 December 2020

Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men

1 reference

12 December 2020

Indinavir concentrations and antiviral effect

1 reference

12 December 2020

Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

1 reference

12 December 2020

Regression of HIV-associated progressive encephalopathy of childhood during HAART

1 reference

12 December 2020

Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid

1 reference

12 December 2020

Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease

1 reference

12 December 2020

The Blood-Brain Barrier

1 reference

12 December 2020

Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.

1 reference

12 December 2020

Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection.

1 reference

12 December 2020

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

1 reference

12 December 2020

HIV protease inhibitors: pharmacologic and metabolic distinctions

1 reference

12 December 2020

Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

1 reference

12 December 2020

10.2165/00023210-200216090-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference